Literature DB >> 11953598

Pathologic neovascularization in cartilage tumors.

Richard L McGough1, Bassam I Aswad, Richard M Terek.   

Abstract

Tumor-induced angiogenesis is necessary to sustain radial growth of tumors. Increased microvascularity has been correlated with increased metastatic potential in breast, gastrointestinal, and gynecologic tumors, but has not been well studied in cartilaginous tumors. Grade II and Grade III chondrosarcomas have increased metastatic potential compared with Grade I tumors. One reason for this may be pathologic neovascularization. The purpose of the current study was to quantify the microvessel density of cartilage tumors. Seven Grade III, 17 Grade II, and eight Grade I chondrosarcomas, and 22 benign cartilage tumors were examined. Specimens were stained with antiCD34 antibody. Microvessel densities then were determined by direct counting and estimated using the Chalkley technique. Microvessel densities for Grade III and Grade II chondrosarcomas were 45.9 and 46.2 per high-power field and for Grade I and benign tumors the microvessel densities were 9.3 and 10.3. Microvessel densities of the aggressive tumors (Grades III and II) were greater than the microvessel densities of the nonaggressive tumors (Grade I and benign). Chalkley estimates confirmed the results. Microvascularity in cartilage tumors correlates with their biologic aggressiveness and seems promising as a variable to help with histopathologic grading and as a target for new treatment modalities.

Entities:  

Mesh:

Year:  2002        PMID: 11953598     DOI: 10.1097/00003086-200204000-00011

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  10 in total

1.  miR-181a Targets RGS16 to Promote Chondrosarcoma Growth, Angiogenesis, and Metastasis.

Authors:  Xiaojuan Sun; Cherie Charbonneau; Lei Wei; Qian Chen; Richard M Terek
Journal:  Mol Cancer Res       Date:  2015-05-26       Impact factor: 5.852

2.  New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis.

Authors:  Jonathan Cm Clark; Toru Akiyama; Crispin R Dass; Peter Fm Choong
Journal:  Cancer Cell Int       Date:  2010-06-28       Impact factor: 5.722

3.  CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.

Authors:  Xiaojuan Sun; Cherie Charbonneau; Lei Wei; Wentian Yang; Qian Chen; Richard M Terek
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

4.  MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

5.  HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

6.  Diversity of angiogenesis among malignant bone tumors.

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Koji Arihiro; Mitsuo Ochi
Journal:  Mol Clin Oncol       Date:  2012-08-10

7.  Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.

Authors:  Francisco Fontes Cintra; Mauricio Etchebehere; José Carlos Barbi Gonçalves; Alejandro Enzo Cassone; Eliane Maria Ingrid Amstalden
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma.

Authors:  Michele Minopoli; Sabrina Sarno; Gioconda Di Carluccio; Rosa Azzaro; Susan Costantini; Flavio Fazioli; Michele Gallo; Gaetano Apice; Lucia Cannella; Domenica Rea; Maria Patrizia Stoppelli; Diana Boraschi; Alfredo Budillon; Katia Scotlandi; Annarosaria De Chiara; Maria Vincenza Carriero
Journal:  Cells       Date:  2020-04-24       Impact factor: 6.600

Review 9.  Non-Conventional Treatments for Conventional Chondrosarcoma.

Authors:  Varun Monga; Hariharasudan Mani; Angela Hirbe; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2020-07-19       Impact factor: 6.639

10.  Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.

Authors:  Robin L Jones; Daniela Katz; Elizabeth T Loggers; Darin Davidson; Eve T Rodler; Seth M Pollack
Journal:  Med Oncol       Date:  2017-08-29       Impact factor: 3.064

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.